Amgen Plays Both Sides As It Builds Out Inflammation Biosimilars
Remicade Biosimilar Avsola Launched In July
Amgen has reiterated the strength and capabilities of its dual commercial model by suggesting it will replicate its strategy for oncology biosimilars for its burgeoning inflammation product portfolio.
